Jun Shengtai will present the htd1801 study data at the 2019 annual meeting of the American Association for the Study of Hepatology

Junsantai announced that several preclinical studies of the company's innovative HTD1801 will be presented in oral reports and wall reports at the 70th Annual Meeting of the American Association for the Study of Hepatology (AASLD) in 2019, in Boston, USA, November 8-12.
The Liver Meeting is the world's largest and most authoritative liver disease conference, with nearly 10,000 liver disease professionals from around the world attending each year to share breakthrough research findings, new treatment guidelines and the latest treatment advances in the field of hepatology.
Developed by the Junsantai team, HTD1801 is conducting Phase II clinical trials in the United States for non-alcoholic fatty hepatitis (NASH) and primary sclerotic bileitis (PSC). HTD1801 has obtained FDA fast-track eligibility and PSC orphan drug certification for both adaptations. Phase II clinical data are expected to be released in 2020. (Medical Rubik's Cube)